Repligen Corp
RGEN160.591USD
+3.201+2.03%
Market hours （ET）Quotes delayed by 15 min
9.04BMarket Cap
5755.96P/E TTM
More Details of Repligen Corp Company
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Repligen Corp Info
Ticker SymbolRGEN
Company nameRepligen Corp
IPO dateApr 29, 1986
CEOLoeillot (Olivier)
Number of employees1778
Security typeOrdinary Share
Fiscal year-endApr 29
AddressBuilding 1, Suite 100
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02453
Phone17814499560
Websitehttps://www.repligen.com/
Ticker SymbolRGEN
IPO dateApr 29, 1986
CEOLoeillot (Olivier)
Company Executives of Repligen Corp
Name
Name/Position
Position
Shareholding
Change
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.02K
-53.90%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason K. Garland
Mr. Jason K. Garland
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Martin D. Madaus, Ph.D.
Dr. Martin D. Madaus, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.02K
-53.90%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
North America
89.36M
49.00%
Europe
69.30M
38.00%
APAC/Other
23.71M
13.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.94%
BlackRock Institutional Trust Company, N.A.
8.24%
T. Rowe Price Associates, Inc.
6.14%
Roy T. Eddleman UEO
5.88%
United Capital Financial Advisors, LLC
4.90%
Other
65.91%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.94%
BlackRock Institutional Trust Company, N.A.
8.24%
T. Rowe Price Associates, Inc.
6.14%
Roy T. Eddleman UEO
5.88%
United Capital Financial Advisors, LLC
4.90%
Other
65.91%
Shareholder Types
Shareholders
Proportion
Investment Advisor
59.79%
Investment Advisor/Hedge Fund
29.04%
Hedge Fund
15.73%
Individual Investor
6.33%
Research Firm
2.20%
Pension Fund
2.00%
Bank and Trust
0.71%
Sovereign Wealth Fund
0.60%
Family Office
0.50%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1027
55.23M
98.12%
-6.26M
2025Q2
1028
61.98M
110.32%
-3.21M
2025Q1
1054
62.91M
111.98%
-2.72M
2024Q4
1054
61.13M
109.11%
-3.76M
2024Q3
1046
60.75M
108.48%
-6.10M
2024Q2
1039
61.28M
109.67%
-2.73M
2024Q1
1036
60.56M
108.45%
-5.41M
2023Q4
1062
62.13M
111.29%
-2.30M
2023Q3
1063
61.47M
110.27%
+2.91M
2023Q2
1050
59.01M
105.99%
+1.34M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
5.07M
9%
-2.87K
-0.06%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.71M
8.37%
-180.36K
-3.69%
Jun 30, 2025
T. Rowe Price Associates, Inc.
3.43M
6.1%
-3.13M
-47.69%
Aug 31, 2025
Roy T. Eddleman UEO
3.31M
5.89%
-67.50K
-2.00%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.36M
2.43%
+842.96K
+161.67%
Jun 30, 2025
State Street Investment Management (US)
1.62M
2.88%
-66.31K
-3.93%
Jun 30, 2025
Citadel Advisors LLC
1.06M
1.89%
-266.68K
-20.06%
Jun 30, 2025
Point72 Asset Management, L.P.
1.91M
3.4%
+796.75K
+71.36%
Jun 30, 2025
Holocene Advisors, LP
936.81K
1.67%
-23.17K
-2.41%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
First Trust NYSE Arca Biotechnology Index Fund
3.45%
Alger Mid Cap 40 ETF
3.1%
Congress SMid Growth ETF
2.46%
iShares Health Innovation Active ETF
2.28%
VanEck Biotech ETF
1.34%
Franklin Genomic Advancements ETF
1.23%
Pacer US Export Leaders ETF
1.18%
Alger 35 ETF
1.15%
WisdomTree BioRevolution Fund
1.06%
iShares Biotechnology ETF
0.7%
View more
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.45%
Alger Mid Cap 40 ETF
Proportion3.1%
Congress SMid Growth ETF
Proportion2.46%
iShares Health Innovation Active ETF
Proportion2.28%
VanEck Biotech ETF
Proportion1.34%
Franklin Genomic Advancements ETF
Proportion1.23%
Pacer US Export Leaders ETF
Proportion1.18%
Alger 35 ETF
Proportion1.15%
WisdomTree BioRevolution Fund
Proportion1.06%
iShares Biotechnology ETF
Proportion0.7%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Repligen Corp?
The top five shareholders of Repligen Corp are:
The Vanguard Group, Inc. holds 5.07M shares, accounting for 9.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.71M shares, accounting for 8.37% of the total shares.
T. Rowe Price Associates, Inc. holds 3.43M shares, accounting for 6.10% of the total shares.
Roy T. Eddleman UEO holds 3.31M shares, accounting for 5.89% of the total shares.
Fidelity Management & Research Company LLC holds 1.36M shares, accounting for 2.43% of the total shares.
The Vanguard Group, Inc. holds 5.07M shares, accounting for 9.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.71M shares, accounting for 8.37% of the total shares.
T. Rowe Price Associates, Inc. holds 3.43M shares, accounting for 6.10% of the total shares.
Roy T. Eddleman UEO holds 3.31M shares, accounting for 5.89% of the total shares.
Fidelity Management & Research Company LLC holds 1.36M shares, accounting for 2.43% of the total shares.
What are the top three shareholder types of Repligen Corp?
The top three shareholder types of Repligen Corp are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
T. Rowe Price Associates, Inc.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
T. Rowe Price Associates, Inc.
How many institutions hold shares of Repligen Corp (RGEN)?
As of 2025Q3, 1027 institutions hold shares of Repligen Corp, with a combined market value of approximately 55.23M, accounting for 98.12% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -12.20%.
What is the biggest source of revenue for Repligen Corp?
In FY2025Q2, the -- business generated the highest revenue for Repligen Corp, amounting to -- and accounting for --% of total revenue.
